Table I.
Activity of Aplidin against Cell Lines in the PPTP in Vitro Panel
| Cell Line | Status | Histology | T/C0.1nM (%) | IC50 (nM) |
|---|---|---|---|---|
| RD | Rhabdomyosarcoma | 46.4 | <0.1 | |
| Rh41 | Post-Therapy | Rhabdomyosarcoma | 57.5 | 0.19 |
| Rh18 | Diagnosis | Rhabdomyosarcoma | 96.3 | 5.50 |
| Rh30 | Diagnosis | Rhabdomyosarcoma | 57.3 | 0.23 |
| BT-12 | Diagnosis | Rhabdoid | 24.8 | <0.1 |
| CHLA-266 | Diagnosis | Rhabdoid | 35.7 | <0.1 |
| TC-71 | Post-Therapy | Ewing | 5.5 | <0.1 |
| CHLA-9 | Diagnosis | Ewing | 32.9 | <0.1 |
| CHLA-10 | Post-Therapy | Ewing | 25.3 | <0.1 |
| CHLA-258 | Post-Bone Marrow Transplant | Ewing | 46.7 | <0.1 |
| SJ-GBM2 | Post-Therapy | Glioblastoma | 15.5 | <0.1 |
| NB-1643 | Diagnosis | Neuroblastoma | 79.5 | 0.67 |
| NB-EBc1 | Post-Therapy | Neuroblastoma | 95.4 | 5.70 |
| CHLA-90 | Post-Bone Marrow Transplant | Neuroblastoma | 35.0 | <0.1 |
| CHLA-136 | Post-Bone Marrow Transplant | Neuroblastoma | 82.1 | 6.00 |
| COG-LL-317 | Post-Therapy | ALL T-cell | 3.5 | <0.1 |
| NALM-6 | Post-Therapy | ALL B-precursor | 0.5 | <0.1 |
| RS4;11 | Post-Therapy | ALL B-precursor | 21.6 | <0.1 |
| MOLT-4 | Post-Therapy | ALL T-cell | 8.6 | <0.1 |
| CCRF-CEM | ALL T-cell | 11.0 | <0.1 | |
| Kasumi-1 | Post-Bone Marrow Transplant | AML | 11.4 | <0.1 |
| Karpas-299 | Post-Therapy | ALCL | 8.8 | <0.1 |
| Ramos-RA1 | NHL | 3.7 | <0.1 | |
| Median | 25.3 | <0.1 | ||
| Minimum | 0.5 | <0.1 | ||
| Maximum | 96.3 | 6.00 |